Format

Send to

Choose Destination
J Rheumatol. 1996 Sep;23(9):1550-2.

The use of methotrexate in polymyalgia rheumatica.

Author information

1
Ashland Arthritis Center, Kentucky, USA.

Abstract

OBJECTIVE:

To examine the efficacy and steroid sparing potential of methotrexate (MTX) in the treatment of polymyalgia rheumatica (PMR) without giant cell arteritis.

METHODS:

43 patients with PMR were treated with MTX 7.5 mg/wk for 3 months. This dose was raised to 10 and finally 12.5 mg/wk MTX if the desired response was not obtained.

RESULTS:

No patient benefitted clinically or statistically from treatment with MTX.

CONCLUSION:

MTX is of no benefit in the treatment of PMR.

PMID:
8877923
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center